A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment

Phase 3

Terminated

Conditions: Chronic Thromboembolic Pulmonary Hypertension

Interventions: Drug: Placebo
Drug: Selexipag

Registration Number: NCT03689244

Lead Sponsor: Actelion

Brief Summary: Selexipag is available in many countries for the treatment of pulmonary arterial hypertension (PAH). Due to the similarities between PAH and chronic thromboembolic pulmonary hypertension (CTEPH) and the observed efficacy of other PAH medicines in CTEPH, it is believed that selexipag could benefit to patients with CTEPH. This study aims to assess the efficacy and safety of selexipag in participants with inoperable or persistent/recurrent CTEPH.

Detailed Description: Participants will be recruited in two sequential cohorts: approximately the first 90 randomized participants will undergo a right heart catheterization (RHC) (and left heart catheterization LHC, if needed) with measurement of pulmonary vascular resistance (PVR) at Week 20 and will constitute the hemodynamic cohort; the remaining participants will constitute the non-hemodynamic cohort; who do not require a post-baseline hemodynamic assessment. They will undergo the same overall study assessments as the hemodynamic cohort excepted for RHC at Week 20.

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 128

Inclusion Criteria

Signed and dated informed consent form
Male and female participants from greater than or equal to (>) 18 (or the legal age of consent in the jurisdiction in which the study is taking place) and less then or equal to (<=85) years old at Screening (Visit 1)
With established diagnosis of inoperable CTEPH (i.e., technically non-operable) or persistent/recurrent CTEPH after pulmonary endarterectomy (PEA) and/or balloon pulmonary angioplasty (BPA), as confirmed by the corresponding adjudication committee
With pulmonary hypertension (PH) in WHO FC I-IV.
Participant able to perform the 6-minute walk test (6MWT) with a minimum distance of 100 m and a maximum distance of 450 m at screening visit.
Women of childbearing potential must have a negative pregnancy test at screening and randomization and must agree to undertake monthly urine pregnancy tests, and to use a reliable method of birth control from screening visit up to at least 30 days after study treatment discontinuation. If a hormonal contraceptive is chosen it must be taken for at least 1 month prior to randomization.

Main

Exclusion Criteria

Planned or current treatment with another investigational treatment up to 3 months prior to randomization.
Any known factor or disease that might interfere with treatment compliance, study conduct, or interpretation of the results, such as drug or alcohol dependence or psychiatric disease.
Known concomitant life-threatening disease with a life expectancy < 12 months.
Planned balloon pulmonary angioplasty within 26 weeks after randomization.
Change in dose or initiation of new PH-specific therapy within 90 days prior to the baseline RHC (and LHC, if needed) qualifying for enrollment for the hemodynamic cohort and within 90 days prior to randomization (Visit 2) for the non-hemodynamic cohort
Treatment with prostacyclin (epoprostenol), prostacyclin analogs (i.e., treprostinil, iloprost, beraprost) or prostacyclin receptor agonists (i.e., selexipag) within 90 days prior to randomization (visit 2) except those given at vasodilator testing during RHC
Change in dose or initiation of new diuretics and/or calcium channel blockers within 1 week prior to baseline RHC (and LHC, if needed)
Any co-morbid condition that may influence the ability to perform a reliable and reproducible 6MWT, including use of walking aids (cane, walker, etc).
Any other criteria as per selexipag Summary of Product Characteristics (SmPC).
Exclusion criteria related to comorbidities: severe coronary heart disease or unstable angina as assessed by the investigator; mocardial infarction within the last 6 months prior to or during Screening; decompensated cardiac failure if not under close supervision; severe arrhythmias as assessed by the investigator; cerebrovascular events (example transient ischemic attack, stroke) within the last 3 months prior to or during screening; congenital or acquired valvular defects with clinically relevant myocardial function disorders not related to pulmonary hypertension. (PH); known or suspicion of pulmonary veno-occlusive disease

Study & Design

Study Type: INTERVENTIONAL

Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Placebo DB	Placebo	During the double-blind treatment period, participants in this group will receive the oral matching placebo, twice daily. A (mock) up-titration scheme will be followed.
Selexipag DB	Selexipag	During the double blind treatment period, participants in this group will receive selexipag. Each participant will start with one oral tablet of selexipag 200 µg in the evening of Day 1 and will continue with 200 µg twice daily (b.i.d.) on Day 2. If this dose is well-tolerated, selexipag is up-titrated with weekly increments of 200 µg until reaching the individual maximal tolerated dose (iMTD) in the range of 200 to 1600 µg b.i.d. The up-titration period up to Week 12 is followed by a stable maintenance treatment period from Week 12 to Week 26, at the iMTD. After Week 26, further up-titration can be allowed (but not above 1600 µg b.i.d.).
Selexipag OL	Selexipag	All participants who completed the double-blind treatment period, whether they received placebo or selexipag during the double-blind period, will receive selexipag during the open-label extension period, using the same up-titration schedule as in the double-blind period.

Primary Outcome Measures

Name	Time	Method
Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 20	Baseline (Day 1, pre-dose), within 2 to 5 hours post-dose on Week 20	Change from baseline in PVR at Week 20 was reported. PVR was measured by accessing the vessel either from right heart catheterization or left heart catheterization, if required. Change from baseline in PVR was measured as percent ratio of post treatment value (Week 20) to pre-treatment value (baseline).

Secondary Outcome Measures

Name	Time	Method

Trial Locations

Locations (162): University of California San Diego Medical Center
🇺🇸
La Jolla, California, United States
University of Southern California, Keck School of Medicine
🇺🇸
Los Angeles, California, United States
University of Colorado Anschutz Medical Campus
🇺🇸
Aurora, Colorado, United States
Colorado Springs Pulmonary Consultants
🇺🇸
Colorado Springs, Colorado, United States
South Denver Cardiology Associates PC
🇺🇸
Littleton, Colorado, United States
Mayo Clinic in Florida
🇺🇸
Jacksonville, Florida, United States
Piedmont Healthcare
🇺🇸
Atlanta, Georgia, United States
Emory University
🇺🇸
Atlanta, Georgia, United States
Northwestern University Feinberg School of Medicine
🇺🇸
Chicago, Illinois, United States
University of Chicago Hospitals - Chicago
🇺🇸
Chicago, Illinois, United States
Scroll for more (152 remaining)
University of California San Diego Medical Center
🇺🇸La Jolla, California, United States